BRPI0212545B8 - método ex vivo ou in vitro para produzir uma população de célula dendrítica madura e método para produzir células t - Google Patents

método ex vivo ou in vitro para produzir uma população de célula dendrítica madura e método para produzir células t

Info

Publication number
BRPI0212545B8
BRPI0212545B8 BRPI0212545A BR0212545A BRPI0212545B8 BR PI0212545 B8 BRPI0212545 B8 BR PI0212545B8 BR PI0212545 A BRPI0212545 A BR PI0212545A BR 0212545 A BR0212545 A BR 0212545A BR PI0212545 B8 BRPI0212545 B8 BR PI0212545B8
Authority
BR
Brazil
Prior art keywords
cells
producing
vivo
dendritic cell
cell population
Prior art date
Application number
BRPI0212545A
Other languages
English (en)
Portuguese (pt)
Other versions
BR0212545A (pt
BRPI0212545B1 (pt
BRPI0212545A8 (pt
Inventor
L Bosch Marnix
Original Assignee
Northwest Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Biotherapeutics Inc filed Critical Northwest Biotherapeutics Inc
Publication of BR0212545A publication Critical patent/BR0212545A/pt
Publication of BRPI0212545A8 publication Critical patent/BRPI0212545A8/pt
Publication of BRPI0212545B1 publication Critical patent/BRPI0212545B1/pt
Publication of BRPI0212545B8 publication Critical patent/BRPI0212545B8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/72—Undefined extracts from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
BRPI0212545A 2001-09-06 2002-09-06 método ex vivo ou in vitro para produzir uma população de célula dendrítica madura e método para produzir células t BRPI0212545B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31759201P 2001-09-06 2001-09-06
PCT/US2002/028620 WO2003022215A2 (en) 2001-09-06 2002-09-06 Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response

Publications (4)

Publication Number Publication Date
BR0212545A BR0212545A (pt) 2005-01-18
BRPI0212545A8 BRPI0212545A8 (pt) 2019-10-15
BRPI0212545B1 BRPI0212545B1 (pt) 2019-12-03
BRPI0212545B8 true BRPI0212545B8 (pt) 2021-05-25

Family

ID=32654226

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0212545A BRPI0212545B8 (pt) 2001-09-06 2002-09-06 método ex vivo ou in vitro para produzir uma população de célula dendrítica madura e método para produzir células t

Country Status (17)

Country Link
US (2) US20050059151A1 (https=)
EP (3) EP1441591B1 (https=)
JP (3) JP2005505270A (https=)
KR (3) KR20050027163A (https=)
CN (2) CN1636229B (https=)
AU (1) AU2008221592B2 (https=)
BR (1) BRPI0212545B8 (https=)
CA (1) CA2459713C (https=)
DK (2) DK2322603T3 (https=)
ES (2) ES2598109T3 (https=)
IL (3) IL160720A0 (https=)
MX (1) MXPA04002147A (https=)
NO (2) NO338147B1 (https=)
NZ (1) NZ531530A (https=)
PL (1) PL372098A1 (https=)
PT (2) PT2322603T (https=)
WO (1) WO2003022215A2 (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT412145B (de) * 2002-09-13 2004-10-25 Forsch Krebskranke Kinder Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen
US20040057935A1 (en) * 2002-09-20 2004-03-25 Cedars-Sinai Medical Center Intratumoral delivery of dendritic cells
ES2354944T3 (es) * 2002-12-06 2011-03-21 Northwest Biotherapeutics, Inc. Administración de células dendríticas maduradas parcialmente in vitro para el tratamiento de tumores.
ES2321939T3 (es) * 2003-02-27 2009-06-15 Northwest Biotherapeutics, Inc. Generacion de celulas dendriticas a partir de celulas precursoras dendriticas monociticas con gm-csf en ausencia de citoquinas adicionales.
EP1484064A1 (en) 2003-06-04 2004-12-08 Gesellschaft für Biotechnologische Forschung Therapeutical composition containing dentritic cells and use thereof
WO2005037995A2 (en) * 2003-10-06 2005-04-28 Cedars-Sinai Medical Center Use of cox-2 inhibitor to prevent t-cell anergy induced by dendritic cell therapy
WO2005043155A1 (en) * 2003-10-21 2005-05-12 Cedars-Sinai Medical Center System and method for the treatment of cancer, including cancers of the central nervous system
WO2005042737A1 (ja) * 2003-11-04 2005-05-12 Dnavec Research Inc. 遺伝子導入された樹状細胞の製造方法
WO2006001120A1 (ja) 2004-06-24 2006-01-05 Dnavec Research Inc. マイナス鎖rnaウイルスを含む抗癌剤
KR20080109717A (ko) * 2005-12-08 2008-12-17 노쓰웨스트 바이오써라퓨틱스, 인크. 미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한조성물 및 방법
EP1840206A1 (en) * 2006-03-28 2007-10-03 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Compositions for the preparation of mature dendritic cells
WO2008039874A2 (en) 2006-09-26 2008-04-03 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008039974A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
PL2328923T3 (pl) 2008-09-02 2016-06-30 Cedars Sinai Medical Center Epitopy CD133
EP2427485B1 (en) * 2009-05-07 2016-12-07 ImmunoCellular Therapeutics, Ltd. Cd133 epitopes
HK1202432A1 (en) * 2012-02-02 2015-10-02 Caladrius Biosciences, Inc. Pluripotent germ layer origin antigen presenting cancer vaccine
KR101704745B1 (ko) 2012-05-31 2017-02-08 제이더블유크레아젠 주식회사 수지상세포 성숙화 조성물 및 이를 이용하여 항원 특이적 수지상세포를 제조하는 방법
US9744193B2 (en) 2012-09-06 2017-08-29 Orbis Health Solutions Llc Tumor lysate loaded particles
AU2020203845C1 (en) * 2012-09-06 2022-08-11 Orbis Health Solutions, Llc Tumor lysate loaded particles
AU2013359392C1 (en) 2012-12-12 2016-12-08 Orbis Health Solutions, Llc Compositions and methods for tissue regeneration
US10137182B2 (en) 2013-02-14 2018-11-27 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
CN112891522A (zh) * 2013-09-05 2021-06-04 奥比思健康解决方案有限责任公司 装载了肿瘤裂解物的微粒
WO2015134606A1 (en) 2014-03-05 2015-09-11 Orbis Health Solutions Llc Vaccine delivery systems using yeast cell wall particles
US10599155B1 (en) 2014-05-20 2020-03-24 State Farm Mutual Automobile Insurance Company Autonomous vehicle operation feature monitoring and evaluation of effectiveness
US9972054B1 (en) 2014-05-20 2018-05-15 State Farm Mutual Automobile Insurance Company Accident fault determination for autonomous vehicles
US10223479B1 (en) 2014-05-20 2019-03-05 State Farm Mutual Automobile Insurance Company Autonomous vehicle operation feature evaluation
US11669090B2 (en) 2014-05-20 2023-06-06 State Farm Mutual Automobile Insurance Company Autonomous vehicle operation feature monitoring and evaluation of effectiveness
US10373259B1 (en) 2014-05-20 2019-08-06 State Farm Mutual Automobile Insurance Company Fully autonomous vehicle insurance pricing
US10540723B1 (en) 2014-07-21 2020-01-21 State Farm Mutual Automobile Insurance Company Methods of providing insurance savings based upon telematics and usage-based insurance
US11127290B1 (en) 2014-11-13 2021-09-21 State Farm Mutual Automobile Insurance Company Autonomous vehicle infrastructure communication device
CN107849537A (zh) * 2015-06-30 2018-03-27 西北生物治疗药物公司 诱发改善的或增加的抗肿瘤免疫应答的经最佳活化的树突细胞
EP3317402B1 (en) 2015-06-30 2024-02-14 Universidade Nova de Lisboa A viable cell population, method for production and uses thereof
US10163350B1 (en) 2015-08-28 2018-12-25 State Farm Mutual Automobile Insurance Company Vehicular driver warnings
US11242051B1 (en) 2016-01-22 2022-02-08 State Farm Mutual Automobile Insurance Company Autonomous vehicle action communications
US10395332B1 (en) 2016-01-22 2019-08-27 State Farm Mutual Automobile Insurance Company Coordinated autonomous vehicle automatic area scanning
US10747234B1 (en) 2016-01-22 2020-08-18 State Farm Mutual Automobile Insurance Company Method and system for enhancing the functionality of a vehicle
US10324463B1 (en) 2016-01-22 2019-06-18 State Farm Mutual Automobile Insurance Company Autonomous vehicle operation adjustment based upon route
US11719545B2 (en) 2016-01-22 2023-08-08 Hyundai Motor Company Autonomous vehicle component damage and salvage assessment
US11441916B1 (en) 2016-01-22 2022-09-13 State Farm Mutual Automobile Insurance Company Autonomous vehicle trip routing
US10134278B1 (en) 2016-01-22 2018-11-20 State Farm Mutual Automobile Insurance Company Autonomous vehicle application
KR102038114B1 (ko) * 2016-02-26 2019-10-30 주식회사 엘지화학 광학 점착제용 (메타)아크릴레이트기 함유 벤조페논의 제조방법 및 광학 점착제 조성물
WO2018160666A1 (en) * 2017-02-28 2018-09-07 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Short-term activated dc1s and methods for their production and use
WO2019183924A1 (en) * 2018-03-30 2019-10-03 Syz Cell Therapy Co. Improved multiple antigen specific cell therapy methods
AU2020363707A1 (en) * 2019-10-07 2022-04-28 Northwest Biotherapeutics, Inc. In vitro methods and compositions for enhancing the activation of dendritic cells and t cells, and for inducing a th-1 immune response

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US5366866A (en) * 1991-07-25 1994-11-22 Duke University Method of diagnosing ovarian and endometrial cancer with monoclonal antibodies OXA and OXB
US5227471A (en) * 1992-01-30 1993-07-13 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Monoclonal antibody PD41 that binds to a prostate mucin antigen that is expressed in human prostatic carcinoma
US5788963A (en) 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
CA2232865A1 (en) * 1995-10-04 1997-04-10 Immunex Corporation The use of flt3 ligand to generate dendritic cells
US7659119B2 (en) * 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
ATE428769T1 (de) * 1997-10-27 2009-05-15 Univ Rockefeller Methode und zusammensetzung zur herstellung von reifen dendritischen zellen
JP2000143534A (ja) * 1998-11-13 2000-05-23 Asahi Chem Ind Co Ltd 樹状細胞ワクチン及びその製造方法
JP2000279181A (ja) * 1999-04-01 2000-10-10 Japan Science & Technology Corp ヒト樹状細胞の発現遺伝子群
EP1254953A4 (en) * 1999-12-28 2004-06-02 Toyoshima Kumao Maturity-triggering agent for immature dendritic cells
US6247378B1 (en) * 2000-01-06 2001-06-19 Deere & Company Operator control device for an infinitely variable transmission
ES2375948T3 (es) * 2000-05-12 2012-03-07 Northwest Biotherapeutics, Inc. Procedimiento para aumentar la presentación de clase i de ant�?genos exógenos por células dendr�?ticas humanas.
AU2002240877B2 (en) * 2001-01-15 2007-03-29 I.D.M. Immuno-Designed Molecules Ancillary composition for the preparation of committed mature dendritic cells
AU2002326463A1 (en) * 2001-07-25 2003-02-17 Northwest Biotherapeutics, Inc. Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors

Also Published As

Publication number Publication date
ES2598109T3 (es) 2017-01-25
CN1636229A (zh) 2005-07-06
EP2322603A1 (en) 2011-05-18
DK2322603T3 (da) 2020-01-27
EP3653055A1 (en) 2020-05-20
PT1441591T (pt) 2016-10-06
JP5777956B2 (ja) 2015-09-16
EP1441591A2 (en) 2004-08-04
PL372098A1 (en) 2005-07-11
JP2015107133A (ja) 2015-06-11
WO2003022215A2 (en) 2003-03-20
HK1079989A1 (en) 2006-04-21
CA2459713A1 (en) 2003-03-20
US20080254064A1 (en) 2008-10-16
IL160720A0 (en) 2004-08-31
NO338147B1 (no) 2016-08-01
AU2008221592B2 (en) 2012-12-20
WO2003022215A3 (en) 2003-11-13
JP2011188872A (ja) 2011-09-29
JP2005505270A (ja) 2005-02-24
AU2008221592A1 (en) 2008-10-16
EP2322603B1 (en) 2019-10-16
NO20151562A1 (no) 2015-11-16
PT2322603T (pt) 2020-01-21
KR20050027163A (ko) 2005-03-17
KR20140116544A (ko) 2014-10-02
NZ531530A (en) 2007-01-26
CN1636229B (zh) 2012-12-19
CA2459713C (en) 2015-08-18
US20050059151A1 (en) 2005-03-17
MXPA04002147A (es) 2005-03-07
BR0212545A (pt) 2005-01-18
KR20110081341A (ko) 2011-07-13
IL219266A0 (en) 2012-06-28
KR101803702B1 (ko) 2017-12-01
CN102973928B (zh) 2019-03-15
CN102973928A (zh) 2013-03-20
IL160720A (en) 2012-05-31
IL219266A (en) 2014-02-27
JP6114768B2 (ja) 2017-04-12
EP1441591A4 (en) 2006-06-07
NO20040965L (no) 2004-04-23
BRPI0212545B1 (pt) 2019-12-03
BRPI0212545A8 (pt) 2019-10-15
DK1441591T3 (en) 2017-05-22
ES2766299T3 (es) 2020-06-12
EP1441591B1 (en) 2016-06-29

Similar Documents

Publication Publication Date Title
BRPI0212545B8 (pt) método ex vivo ou in vitro para produzir uma população de célula dendrítica madura e método para produzir células t
DK1604016T3 (da) In vitro-fremgangsmåde til differentiering af monocytiske dendritiske precursorceller i umodne dendritiske celler
EP2722387A3 (en) Definitive endoderm
SG131109A1 (en) Muteins of tear lipocalin
WO2003083089A3 (en) Tolerogenic antigen-presenting cells
AU8212301A (en) Method for producing ready to use, antigen loaded or unloaded, cryoconserved mature dendritic cells
NO950534D0 (no) Modufiserte soppceller og fremgangsmåter for fremstilling av rekombinante produkter
DK1809737T3 (da) Sammensætninger med modne dendritceller og fremgangsmåder til dyrkning af disse
CY1107771T1 (el) Μεθοδος για την παραγωγη χονδρινων εμφυτευματων απο in vitro καλλιεργημενα χονδροκυτταρα
WO2007067782A3 (en) Compositions and methods for inducing the activation of immature monocytic dendritic cells
IL196893A0 (en) Site specific incorporation of non-natural amino acids by vertebrate cells
SG165155A1 (en) Novel flavivirus antigens
JP2002517227A5 (ja) 造血幹細胞を試験管内で維持する方法と組成物
NO20074278L (no) Tigecyklinblandinger og fremgangsmater for fremstilling
DK2003969T3 (da) Mature dendritic cell compositions and methods for culturing same
TW200505939A (en) Process for production of cyclic peptides
BR9708220A (pt) Peptìdios de ligação hla-a2.1 e seus usos
BRPI0508629A (pt) trilho lateral para uso com um suporte para paciente
BR0314373A (pt) Produto imunogênico estável para a indução de anticorpos contra uma ou várias proteìnas antigênicas em um indivìduo, composições farmacêutica, imunogênica e de vacina e processo de preparação de um produto imunogênico
IL196900A (en) Autologous T cell vaccine compositions
DE60108661D1 (de) Herstellung und verwendung von dendritischen zellen
HK1040402A1 (zh) 使用乳粘素(lactadherin)或其變體的的方法及其組合物
EP1209226A3 (en) Maturation of dendritic cells by recombinant heat shock protein 70 (hsp70)
WO2004072262A3 (en) Cultured cd14+ antigen presenting cells
AU2003273521A1 (en) Production method of iturin a and its homologues

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT. CL.: A01N 63/00, A61K 45/00, C12N 5/00, C12N 5/02, C12N 5/08.

Ipc: C12N 5/02 (2006.01), C12N 5/0784 (2010.01), A61K 3

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/12/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/12/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/09/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2686 DE 28-06-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.